Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2018 08:00 ET | Source: XBiotech Inc.

XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

AUSTIN, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today additional data analysis of its Phase 2 study evaluating XBiotech’s True Human™ antibody, MABp1, as a...
January 25, 2018 08:00 ET | Source: XBiotech Inc.

XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

AUSTIN, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today the publication of “A Natural Human Monoclonal Antibody Targeting Staphylococcus Protein A Protects...
January 19, 2018 08:00 ET | Source: XBiotech Inc.

XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating...
December 04, 2017 08:00 ET | Source: XBiotech Inc.

XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology

AUSTIN, Texas, Dec. 04, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today the publication of data from its randomized phase 2 study evaluating XBiotech’s True Human™ antibody,...
November 14, 2017 07:30 ET | Source: XBiotech Inc.

XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions

AUSTIN, Texas, Nov. 14, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today a presentation of findings on the role of IL-1 alpha (IL-1α) associated with Neutrophil Extracellular...
November 03, 2017 11:54 ET | Source: XBiotech Inc.

XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions

AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the company’s IL-1 alpha (IL-1α) antibody, will be featured in an oral...
October 18, 2017 10:41 ET | Source: XBiotech Inc.

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of...
October 03, 2017 08:00 ET | Source: XBiotech, Inc

XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board

AUSTIN, Texas, Oct. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) is pleased to announce the appointment of William Levis, MD to its Scientific Advisory Board (SAB). Dr. Levis will work...
September 21, 2017 08:00 ET | Source: XBiotech, Inc

XBiotech to Present at Cantor Fitzgerald’s Global Healthcare Conference

AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald’s Global Healthcare Conference taking place...
September 20, 2017 08:00 ET | Source: XBiotech, Inc

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will...